I attached some good news that was reported in 2023 but I must have missed it. “[b]One of the colchicine site ligands that has successfully passed a phase II clinical trial is verubulin (Azixa, 1) [16,17,18,19] (Figure 1). Since the first reports of verubulin as a potent microtubule-disrupting agent and especially after the suspension of its further clinical promotion due to economic reasons [20], several research groups extensively studied the structure–activity relationship for the series of analogues of the lead molecule (Figure 1) [20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36]. In particular, the following modifications were carried out: the variations of the substituent in position 2 of quinazoline, conformational restriction of 4-methoxy-N-methylaniline moiety, replacement of quinazoline core with other aromatic heterocycles, etc.”
As you all know, Azixa is our little baby. So good news that tests results turned out in our favour. Let’s cross our fingers for the next clinical trial phase. Hula Hula Cuckoo Penny
